Isoniazid inhibits human erythroid 5-aminolevulinate synthase: Molecular mechanism and tolerance study with four X-linked protoporphyria patients.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Biochimica et Biophysica Acta - Molecular Basis of Disease

• Publication date

  2017-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bbadis.2016.11.011PMID 27838491
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pyridoxine-Responsive Anemia in a Patient Receiving Isoniazid*

  2017cited by this paper
• Mechanism of isoniazid‐induced hepatotoxicity: then and now

  2016cited by this paper
• Successful diagnosis of hyperpyrexia induced by isoniazid in a child with suspected extra-pulmonary tuberculosis.

  2015cited by this paper
• Elevated transaminases are common in children on prophylactic treatment for tuberculosis

  2015cited by this paper
• Identification of the Mitochondrial Heme Metabolism Complex

  2015cited by this paper
• Human Erythroid 5-Aminolevulinate Synthase Mutations Associated with X-Linked Protoporphyria Disrupt the Conformational Equilibrium and Enhance Product Release.

  2015cited by this paper
• Unstable Reaction Intermediates and Hysteresis during the Catalytic Cycle of 5-Aminolevulinate Synthase

  2014cited by this paper
• Expression of Murine 5-Aminolevulinate Synthase Variants Causes Protoporphyrin IX Accumulation and Light-Induced Mammalian Cell Death

  2014cited by this paper
• Mechanisms of isoniazid‐induced idiosyncratic liver injury: Emerging role of mitochondrial stress

  2014cited by this paper
• Catalytically active alkaline molten globular enzyme: Effect of pH and temperature on the structural integrity of 5-aminolevulinate synthase.

  2014cited by this paper
• The Molecular Genetics of Mycolic Acid Biosynthesis

  2014cited by this paper
• Molecular Expression and Characterization of Erythroid-Specific 5-Aminolevulinate Synthase Gain-of-Function Mutations Causing X-Linked Protoporphyria

  2013cited by this paper
• Toward Heme: 5-Aminolevulinate Synthase and Initiation of Porphyrin Synthesis

  2013cited by this paper
• Molecular and functional analysis of the C-terminal region of human erythroid-specific 5-aminolevulinic synthase associated with X-linked dominant protoporphyria (XLDPP).

  2013cited by this paper
• Isoniazid: Radical-induced oxidation and reduction chemistry.

  2013cited by this paper
• Sideroblastic Anemias: Molecular Basis, Pathophysiology, and Clinical Aspects

  2013cited by this paper
• Heme Biosynthesis and Pathophysiology of Porphyrias

  2013cited by this paper
• X-linked Sideroblastic Anemia Due to Carboxyl-terminal ALAS2 Mutations That Cause Loss of Binding to the β-Subunit of Succinyl-CoA Synthetase (SUCLA2)*

  2012cited by this paper
• Pyrazinamide‐induced sideroblastic anemia

  2012cited by this paper
• Direct Oxidation and Covalent Binding of Isoniazid to Rodent Liver and Human Hepatic Microsomes: Humans Are More Like Mice than Rats

  2012cited by this paper
• A Novel Mechanism of Growth Phase-dependent Tolerance to Isoniazid in Mycobacteria*

  2012cited by this paper
• A Fresh Look at the Mechanism of Isoniazid‐Induced Hepatotoxicity

  2011cited by this paper
• Molecular enzymology of 5-aminolevulinate synthase, the gatekeeper of heme biosynthesis.

  2011cited by this paper
• Severe isoniazid related sideroblastic anemia

  2011cited by this paper
• Hereditary sideroblastic anemia: pathophysiology and gene mutations

  2010cited by this paper
• Pyridoxal‐5‐phosphate plasma concentrations in children receiving tuberculosis chemotherapy including isoniazid

  2010cited by this paper
• Targeting the Active Site Gate to Yield Hyperactive Variants of 5-Aminolevulinate Synthase*

  2010cited by this paper
• The B6 database: a tool for the description and classification of vitamin B6-dependent enzymatic activities and of the corresponding protein families

  2009cited by this paper
• Serine 254 Enhances an Induced Fit Mechanism in Murine 5-Aminolevulinate Synthase*

  2009cited by this paper
• 5-aminolevulinate synthase: catalysis of the first step of heme biosynthesis.

  2009cited by this paper
• Successful liver transplantation in antituberculosis therapy-induced acute fulminant hepatic failure.

  2009cited by this paper
• DynaFit--a software package for enzymology.

  2009cited by this paper
• Mechanisms for isoniazid action and resistance.

  2008cited by this paper
• C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload.

  2008cited by this paper
• Isoniazid: metabolic aspects and toxicological correlates.

  2007cited by this paper
• Transient Kinetic Studies Support Refinements to the Chemical and Kinetic Mechanisms of Aminolevulinate Synthase*

  2007cited by this paper
• Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice.

  2006cited by this paper
• Mechanisms of action of isoniazid

  2006cited by this paper
• In The Proteomics Protocols Handbook

  2005influential reference
• Crystal structure of 5‐aminolevulinate synthase, the first enzyme of heme biosynthesis, and its link to XLSA in humans

  2005cited by this paper
• How to study proteins by circular dichroism.

  2005cited by this paper
• The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance

  2003cited by this paper
• Transient State Kinetic Investigation of 5-Aminolevulinate Synthase Reaction Mechanism*

  2002cited by this paper
• Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis.

  2002cited by this paper
• Expression of Mammalian 5-Aminolevulinate Synthase in Escherichia coli

  2001cited by this paper
• The genetics and biochemistry of isoniazid resistance in mycobacterium tuberculosis.

  2000cited by this paper
• Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis

  2000cited by this paper
• Interaction between succinyl CoA synthetase and the heme-biosynthetic enzyme ALAS-E is disrupted in sideroblastic anemia.

  2000cited by this paper
• Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis.

  1999cited by this paper
• Pre-steady-state Reaction of 5-Aminolevulinate Synthase

  1999cited by this paper
• Protein identification and analysis tools in the ExPASy server.

  1999cited by this paper
• Mechanisms of the inhibition of human erythrocyte pyridoxal kinase by drugs.

  1997cited by this paper
• Mutations at a glycine loop in aminolevulinate synthase affect pyridoxal phosphate cofactor binding and catalysis.

  1996cited by this paper
• Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase.

  1996cited by this paper
• Molecular regulation of heme biosynthesis in higher vertebrates.

  1995cited by this paper
• Molecular defects of erythroid 5-aminolevulinate synthase in X-linked sideroblastic anemia

  1995cited by this paper
• Expression of Mammalian 5-Aminolevulinate Synthase in

  1993cited by this paper
• Expression of mammalian 5-aminolevulinate synthase in Escherichia coli. Overproduction, purification, and characterization.

  1993cited by this paper
• Anti‐tuberculous drugs and sideroblastic anaemia

  1990cited by this paper
• ANTI-TUBERCULOUS DRUGS AND SIDEROBLASTIC ANAEMIA

  1990cited by this paper
• Comparisons and modifications of the colorimetric assay for delta-aminolevulinic acid synthase.

  1982cited by this paper
• Comparisons and modifications of the colorimetric assay for delta-aminolevulinic acid synthase.

  1982cited by this paper
• Haem Synthesis in Sideroblastic Anaemia

  1979cited by this paper
• [Anemia with hypersideroblastosis during anti-tuberculosis therapy. Cure with vitamin therapy].

  1978cited by this paper
• Mechanism and stereochemistry of enzymic reactions involved in porphyrin biosynthesis.

  1976cited by this paper
• Haem synthesis in sideroblastic anaemia.

  1976influential reference
• Abnormal erythroid maturation in mice induced by isoniazid.

  1975cited by this paper
• Bone marrow delta-aminolevulinic acid synthetase activity in experimental sideroblastic anemia.

  1974cited by this paper
• Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors.

  1969cited by this paper
• Pyridoxine-responsive sideroblastic anemia due to antituberculous drugs.

  1967cited by this paper
• Pyridoxine-responsive anemia conditioned by isonicotinic acid hydrazide.

  1966cited by this paper
• Antituberculous Drugs and Sideroblastic Anaemia

  1965cited by this paper
• Experimental Sideroblastic Anaemia

  1965cited by this paper
• Pyridoxine-responsive anemia in a patient receiving isoniazid.

  1962cited by this paper
• Pyridoxal phosphokinases. II. Effects of inhibitors.

  1961cited by this paper
• Nicotinyl and Isonicotinyl Hydrazones of Pyridoxal

  1954cited by this paper
• Isonicotinyl hydrazones as antitubercular agents and derivatives for identification of aldehydes and ketones.

  1954cited by this paper
• TREATMENT of pulmonary tuberculosis with isoniazid; an interim report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee.

  1952cited by this paper
• Treatment of Pulmonary Tuberculosis with Isoniazid

  1952cited by this paper
• A Series of Cases Illustrating the Use of the Eucalyptus-Air and Dry Dressings

  1885cited by this paper

• The GLYT1 inhibitor bitopertin mitigates erythroid PPIX production and liver disease in erythroid protoporphyria

  2025cites this paper
• Establishment of a Threshold of Toxicological Concern for Pharmaceutical Intermediates based on Historical Repeat-Dose Data and its Application in Setting Health Based Exposure Limits.

  2024cites this paper
• Murine models of erythroid 5ALA synthesis disorders and their conditional synthetic lethal dependency on pyridoxine.

  2024cites this paper
• Causes and Pathophysiology of Acquired Sideroblastic Anemia

  2022cites this paper
• Structural basis for dysregulation of aminolevulinic acid synthase in human disease

  2022cites this paper
• Patent highlights December 2020-January 2021.

  2021cites this paper
• Toxicoproteomic Profiling of hPXR Transgenic Mice Treated with Rifampicin and Isoniazid

  2020cites this paper
• Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.

  2020cites this paper
• Anemia sideroblástica una enfermedad infrecuente de causas múltiples

  2020cites this paper
• Current and innovative emerging therapies for porphyrias with hepatic involvement.

  2019cites this paper
• Sideroblastic Anemia Associated With Isoniazid Prophylaxis in a Person Living With HIV.

  2019cites this paper
• Effects of a new 1,2,3-thiadiazole containing hydrazone antimycobacterial agent on serum and liver biochemical parameters in female mice

  2019cites this paper
• Hypothesis: Metabolic targeting of 5-aminolevulinate synthase by tryptophan and inhibitors of heme utilisation by tryptophan 2,3-dioxygenase as potential therapies of acute hepatic porphyrias.

  2019cites this paper
• Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria.

  2019influential citation
• Anti-Correlation between the Dynamics of the Active Site Loop and C-Terminal Tail in Relation to the Homodimer Asymmetry of the Mouse Erythroid 5-Aminolevulinate Synthase

  2018cites this paper
• Ameliorative Effect of Rutin Against Isoniazid-induced Alterations in Certain Hematological and Biochemical Parameters of Albino Rats

  2017cites this paper
• Hepatoprotective Effect of Rutin Against Oxidative Stress of Isoniazid in Albino Rats

  2017cites this paper